Проведення гемодіалізу / гемодіафільтрації вимагає наявності спеціально підготовленої води, яка є основним компонентом діалізуючого розчину. Джерелом води для діалізу є питна вода, що подається до каскаду очищення, та включає в себе, зокрема, процеси зворотного осмосу (ЗO). Належне очищення води є не лише запорукою безпечності процедури гемодіалізу, але й суттєво впливає на якість та тривалість життя пацієнтів. Контроль хімічної та мікробіологічної якість води, що використовується для діалізу дозволяє уникнути додаткового ризику для пацієнтів, які лікується гемодіалізом / гемодіафільтрацією

Expenses for the treatment of end-stage renal disease (ESRD) patients with dialysis renal replacement therapy (DRRT) during the 2018 year constituted 2 billion 922 million 460 thousand UAH. Reimbursement from the state budget constituted 1 billion 44 million 800 thousand UAH. Expendable materials were the main component of DRRT. The share of the expendable materials price from total cost for hemodialysis and hemodiafiltration constituted 66%, for continuous ambulatory peritoneal dialysis and automatic peritoneal dialysis was 86.3% and 92.2%, respectively. The results of the investigation can be used for the development of a diversification model (state budget – local budgets – other sources) of financial expenses for the provision of dialysis treatment in ESRD patients as a part of the state program (strategy) health care finance and service delivery.

During the global COVID-19 pandemic, there was an urgent need to make complex clinical decisions about the management of chronic kidney disease (CKD)patients. Since a significant number of CKD patients have impaired renal function or receive immunosuppressive (IS) therapy, they belong to a high-risk group for adverse effects of COVID-19 infection. In addition, the overwhelming majority of CKD patients have co-morbidities, which not only increases the risk of SARS-CoV-2 infection, but also the formation of life-threatening complications of COVID-19. Currently, there are no data on the best practices for the management of CKD patients during the COVID-19 pandemic. However, based on the existing research presented by leading renal associations (ERA-EDTA, Kidney Care UK, The Renal Association), NICE Rapid Guidelines on this topic, and our own experience, the expert group of the Ukrainian Association of Nephrologists and Kidney Transplant Specialists has created the Adapted Clinical Recommendations for the Management Of Patients with CKD stages 1-4 during the COVID-19 pandemic. The proposed clinical guidelines aimed to classify all CKD patients at risk for SARS-CoV-2 infection and hospitalization. The key characteristics of each class of kidney disease are the kidney functional level, determined by the glomerular filtration rate (GFR), daily urinary protein excretion, hypertension, medication intake and other additional characteristics. All of the following clinical guidelines have a level of evidence of 2C.

Institute of Nephrology of the AMS of Ukraine was established in 2001. Today the Institute constitutesserves as national center in nephrology field. Scientific achievements of the institute staff are known both in Ukraine and abroad scientific achievements of the institute. The aim. Analysis of results and forecast of activities of SI "Institute of Nephrology of the NAMS of Ukraine".

Abstract. The Institute of Nephrology of the Academy of Medical Sciences of Ukraine was established in 2001. Since then, the Institute has been constantly evolving and, currently, it is a national scientific, methodological and medical center in the field of nephrology. The achievements of the Institute's staff are recognized in Ukraine and the world scientific community. The article presents an analysis of the results of the Institute's activities for 2001-2021.